Access to Innovative Treatments Act of 2026 provides a review process for adverse national coverage determinations for drugs under Medicare.

The Access to Innovative Treatments Act of 2026 amends the Social Security Act to establish a review process for adverse national coverage determinations for drugs and biologicals under Medicare. The bill prohibits the application of certain existing national coverage determinations to newly approved drugs and biologicals. It mandates a 90-day review period for requests, a 30-day public comment period, and a final decision within 120 days.

Access to Innovative Treatments Act of 2026 provides a review process for adverse national coverage determinations for drugs under Medicare.

The Access to Innovative Treatments Act of 2026 amends the Social Security Act to establish a review process for adverse national coverage determinations for drugs and biologicals under Medicare. The bill prohibits the application of certain existing national coverage determinations to newly approved drugs and biologicals. It mandates a 90-day review period for requests, a 30-day public comment period, and a final decision within 120 days.